586 related articles for article (PubMed ID: 11992038)
1. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
[TBL] [Abstract][Full Text] [Related]
2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
4. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS
J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323
[TBL] [Abstract][Full Text] [Related]
7. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
8. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
9. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
Khriguian J; Tsui JMG; Vaughan R; Kucharczyk MJ; Nabid A; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Mohiuddin M; Niazi T
J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
Higano C; Shields A; Wood N; Brown J; Tangen C
Urology; 2004 Dec; 64(6):1182-6. PubMed ID: 15596194
[TBL] [Abstract][Full Text] [Related]
12. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
13. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
14. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
15. Effect of androgen suppression on bone mineral density in patients with prostate cancer.
Chernichenko OA; Sakalo VS; Yakovlev PG; Sakalo AV; Zhylchuk YV; Zsolt A
Exp Oncol; 2014 Dec; 36(4):276-8. PubMed ID: 25537224
[TBL] [Abstract][Full Text] [Related]
16. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Yu EY; Kuo KF; Gulati R; Chen S; Gambol TE; Hall SP; Jiang PY; Pitzel P; Higano CS
J Clin Oncol; 2012 May; 30(15):1864-70. PubMed ID: 22493411
[TBL] [Abstract][Full Text] [Related]
17. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation in prostate cancer and the long-term risk of fracture.
Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
[TBL] [Abstract][Full Text] [Related]
19. Changes in body composition during androgen deprivation therapy for prostate cancer.
Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
